Literature DB >> 33075471

Design of bivalent ligands targeting putative GPCR dimers.

Boshi Huang1, Celsey M St Onge1, Hongguang Ma1, Yan Zhang2.   

Abstract

G protein-coupled receptors (GPCRs) have been exploited as primary targets for drug discovery, and GPCR dimerization offers opportunities for drug design and disease treatment. An important strategy for targeting putative GPCR dimers is the use of bivalent ligands, which are single molecules that contain two pharmacophores connected through a spacer. Here, we discuss the selection of pharmacophores, the optimal length and chemical composition of the spacer, and the choice of spacer attachment points to the pharmacophores. Furthermore, we review the most recent advances (from 2018 to the present) in the design, discovery and development of bivalent ligands. We aim to reveal the state-of-the-art design strategy for bivalent ligands and provide insights into future opportunities in this promising field of drug discovery.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33075471      PMCID: PMC7856001          DOI: 10.1016/j.drudis.2020.10.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  59 in total

1.  Locking the dimeric GABA(B) G-protein-coupled receptor in its active state.

Authors:  Julie Kniazeff; Pierre-Philippe Saintot; Cyril Goudet; Jianfeng Liu; Annie Charnet; Gilles Guillon; Jean-Philippe Pin
Journal:  J Neurosci       Date:  2004-01-14       Impact factor: 6.167

2.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Authors:  David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  Dopamine D2 receptor dimers and receptor-blocking peptides.

Authors:  G Y Ng; B F O'Dowd; S P Lee; H T Chung; M R Brann; P Seeman; S R George
Journal:  Biochem Biophys Res Commun       Date:  1996-10-03       Impact factor: 3.575

4.  Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.

Authors:  Yunyun Yuan; Christopher K Arnatt; Guo Li; Kendra M Haney; Derong Ding; Joanna C Jacob; Dana E Selley; Yan Zhang
Journal:  Org Biomol Chem       Date:  2012-02-22       Impact factor: 3.876

5.  2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts.

Authors:  Amy Hauck Newman; Francisco O Battiti; Alessandro Bonifazi
Journal:  J Med Chem       Date:  2019-09-24       Impact factor: 7.446

6.  Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5).

Authors:  Eyup Akgün; Muhammad I Javed; Mary M Lunzer; Michael D Powers; Yuk Y Sham; Yoshikazu Watanabe; Philip S Portoghese
Journal:  J Med Chem       Date:  2015-10-20       Impact factor: 7.446

7.  Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice.

Authors:  Keith M Olson; Attila Keresztes; Jenna K Tashiro; Lisa V Daconta; Victor J Hruby; John M Streicher
Journal:  J Med Chem       Date:  2018-07-16       Impact factor: 7.446

8.  Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits.

Authors:  Dong Wang; Vivianne L Tawfik; Gregory Corder; Sarah A Low; Amaury François; Allan I Basbaum; Grégory Scherrer
Journal:  Neuron       Date:  2018-03-22       Impact factor: 17.173

9.  Crystal structure of jumping spider rhodopsin-1 as a light sensitive GPCR.

Authors:  Niranjan Varma; Eshita Mutt; Jonas Mühle; Valérie Panneels; Akihisa Terakita; Xavier Deupi; Przemyslaw Nogly; Gebhard F X Schertler; Elena Lesca
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-27       Impact factor: 11.205

10.  Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists.

Authors:  Tobias Claff; Jing Yu; Véronique Blais; Nilkanth Patel; Charlotte Martin; Lijie Wu; Gye Won Han; Brian J Holleran; Olivier Van der Poorten; Kate L White; Michael A Hanson; Philippe Sarret; Louis Gendron; Vadim Cherezov; Vsevolod Katritch; Steven Ballet; Zhi-Jie Liu; Christa E Müller; Raymond C Stevens
Journal:  Sci Adv       Date:  2019-11-27       Impact factor: 14.136

View more
  6 in total

1.  Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface.

Authors:  Lei Liu; Zhiran Fan; Xavier Rovira; Li Xue; Salomé Roux; Isabelle Brabet; Mingxia Xin; Jean-Philippe Pin; Philippe Rondard; Jianfeng Liu
Journal:  Elife       Date:  2021-12-06       Impact factor: 8.140

2.  Chemical biology-based approaches to study adenosine A2A - dopamine D2 receptor heteromers.

Authors:  Karen J Gregory; Manuela Jörg
Journal:  Purinergic Signal       Date:  2022-03-29       Impact factor: 3.765

3.  Homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide improved HER2-overexpressed tumor targeting and imaging.

Authors:  Fatemeh Ebrahimi; Zohreh Noaparast; Seyed Mohammad Abedi; Seyed Jalal Hosseinimehr
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 4.  Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.

Authors:  Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

Review 5.  Biased, Bitopic, Opioid-Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction.

Authors:  Robert Root-Bernstein
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-10

Review 6.  Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting.

Authors:  David Speck; Gunnar Kleinau; Michal Szczepek; Dennis Kwiatkowski; Rusan Catar; Aurélie Philippe; Patrick Scheerer
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-19       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.